Drug intelligence / Profile preview

SNA017

Development stage: Preclinical
Lead developer: SmartNuclide
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SNA017 is a radiopharmaceutical candidate developed by SmartNuclide (Suzhou SmartNuclide Biopharmaceutical) that targets the thyroid-stimulating hormone (TSH) pathway. It is being developed as a theranostic agent, encompassing both a diagnostic imaging component for solid tumors and a therapeutic component for the treatment of breast cancer and gastric cancer. The agent leverages the specificity of TSH-related markers to deliver radioisotopes for either visualization or targeted cytotoxicity. As of the latest pipeline updates, SNA017 is in preclinical development.

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on SNA017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNA017.

Explore the full profile